FindTrial
Sign In

Diamyd

DRUG7 trials

Sponsors

Norwegian University Of Science And Technolology, Diamyd Medical AB, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lund University

Conditions

Autoimmune DiabetesAutoimmune DiseasesDiabetes MellitusDiabetes Mellitus Type 1Diabetes Mellitus, Type 1Endocrine System DiseasesGlucose Metabolism DisordersImmune System Diseases

Phase 2

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
TerminatedNCT00837759
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Autoimmune Diabetes, Diabetes Mellitus Type 1
Start: 2009-02-28End: 2011-03-31Updated: 2013-01-03
Diabetes Prevention - Immune Tolerance
CompletedNCT01122446
Lund UniversityPrediabetes, Type 1 Diabetes
Start: 2009-04-30End: 2016-12-31Updated: 2019-05-06
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
CompletedNCT03345004
Diamyd Medical ABAutoimmune Diabetes, Autoimmune Diseases, Diabetes Mellitus +9
Start: 2017-12-20End: 2021-04-27Updated: 2023-01-09
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes
Active, not recruitingNCT05683990
Diamyd Medical ABAutoimmune Diseases, Diabetes Mellitus, Type 1, Prevention
Start: 2024-07-09End: 2028-03-31Updated: 2026-04-20
A follow-up project on the GADinLADA trial to test for the continued impact of HLA-DR3DQ2 on diabetes status and immune parameters 3 years after treatment with intranodal GAD-alum.
Not yet recruitingCTIS2023-509021-53-00
Norwegian University Of Science And TechnolologyLatent Autoimmune Diabetes in Adults (LADA)
Target: 14Updated: 2025-07-21
DiaPrecise, A Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® in individuals at risk for Type 1 diabetes carrying the HLA DR3-DQ2 haplotype
RecruitingCTIS2024-513350-30-00
Diamyd Medical ABType 1 diabetes mellitus
Start: 2024-07-09Target: 16Updated: 2025-11-24

Phase 3

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype
Active, not recruitingCTIS2024-513304-33-00
Diamyd Medical ABType 1 diabetes mellitus
Start: 2022-03-17Target: 280Updated: 2025-07-28

Related Papers

Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
The Journal of Clinical Endocrinology & Metabolism2022-06-0629 citations